Ipamorelin Peptide Dosing Guide: Timing, Protocol & Side Effects (2026)

Ipamorelin is a small research peptide. It tells the body to release its own growth hormone in short, natural pulses. It is sometimes called NNC 26-0161. Novo Nordisk first studied it in the late 1990s.

Most research protocols use 100 to 300 mcg per shot, one to three times per day. The shot goes under the skin (subcutaneous). Ipamorelin has a short half-life of about two hours, so each shot creates one clean GH pulse and then fades.

What makes ipamorelin stand out is how clean it is. Other peptides in its family (GHRP-2, GHRP-6) also raise cortisol, prolactin, and other hormones you do not want raised. Ipamorelin does not do that, even at high doses. That is why most research protocols pick it first.

Need exact syringe units for your vial? Use the Pep Pal calculator to lock in the draw volume.

Ipamorelin is dosed in micrograms (mcg), not milligrams. The most common research protocols build slowly from a small starting dose so users can spot side effects early. The schedule below is the structure most often cited in research-community protocols. There are no FDA-approved dosing guidelines for the GH-related uses people care about today.

There is no approved daily subcutaneous ipamorelin dose. Community-reported research schedules often describe the daily total by combining one or more administrations. The total depends on the amount used each time and how often the schedule repeats. Published research and community protocols are separate evidence levels.

Research suggests GH release climbs with dose up to about 300 mcg per shot, then flattens out. Going higher does not add more GH pulse, but it can add more side effects. That is the practical ceiling in community protocols.

The two-hour half-life is the reason for the one-to-three-shots-per-day range. One shot gives one clean GH pulse. Two or three shots stretch the GH-pulse coverage across the day. Many users start with the bedtime shot only because GH naturally surges during deep sleep.

Community protocols commonly describe dosing on an empty stomach, typically 1-2 hours after a meal and 20-30 minutes before eating again. Food raises insulin, and insulin blunts the GH pulse. Bedtime dosing is often easiest to time because most people stop eating a few hours before sleep.

Published research has not established separate standard subcutaneous ipamorelin doses for men and women. Community protocols may use similar schedules for both sexes, but those schedules are not clinically validated. Any sex-specific claim should be tied to published evidence rather than assumed from community practice.

Some research-community protocols describe 100-200 mcg per administration for women. That range already falls within the broader community schedule on this page. It is not a proven women-specific dose range.

Published studies do not establish one standard subcutaneous frequency for community peptide protocols. Community schedules may describe once-daily or divided administrations, depending on the protocol. These schedules are community-reported and should not be treated as clinically proven.

Community protocols often describe 8 to 12 weeks on, followed by 4 weeks off. Some extend the on-period to week 16. No clinical trial has validated these cycle lengths or shown that an off-period keeps the GH receptor responsive. For a deeper look at duration and schedule structure, see the Ipamorelin Cycle Guide.

Ipamorelin ships as a freeze-dried powder. You add bacteriostatic (BAC) water to dissolve it before drawing your shot. The table below lists common vial sizes, the BAC water volume that gives clean math, the resulting concentration, and the syringe units on a U-100 insulin syringe.

Vial strength is the total amount of ipamorelin in the vial. It is not the amount used in one administration. A 10 mg vial contains more total material than a 5 mg vial, but the draw volume still depends on how the vial was reconstituted.

The number of research administrations a vial can provide depends on the amount used each time. The reconstitution calculator can compare concentrations without changing the underlying mcg amount.

There is no single ipamorelin dose in mL. The draw volume depends on the vial amount and how much bacteriostatic water was added. The same mcg amount can equal a different number of mL or U-100 syringe units at a different concentration.

Use the concentration created during reconstitution to convert the target mcg amount into mL or syringe units. On a U-100 syringe, 100 units = 1 mL and 1 unit = 0.01 mL. The table below shows this math for the vial setups used on this page.

Published human trials did not establish an approved subcutaneous ipamorelin dosage. The chart below summarizes community-reported research schedules for educational comparison only. These schedules should not be treated as clinically validated dosing.

Ipamorelin works by pressing a specific 'release GH' button in the brain. That button is a receptor on the pituitary gland called GHS-R1a. It is the same receptor that the hunger hormone ghrelin uses.

When ipamorelin binds to GHS-R1a, the pituitary releases a pulse of growth hormone. The pulse mimics the way your body already releases GH on its own. It does not flood the system with a constant supply, which is what direct GH injections do.

Your body has a natural 'brake' on GH release. The brake is a hormone called somatostatin. Ipamorelin appears to ease that brake during a short window. This is one reason bedtime dosing is common — it lines up with a natural dip in somatostatin activity.

Once GH is released, the liver converts most of it into IGF-1. IGF-1 is the second signal that drives most of the effects people link to GH — muscle protein building, fat metabolism, and tissue repair. These effects stay under the body's normal feedback controls, so they scale with the GH pulse rather than running unchecked.

The defining feature of ipamorelin is what it leaves alone. In lab studies by Raun et al. (1998), ipamorelin did not raise cortisol, ACTH, or prolactin even at doses many times higher than needed to release GH. Other GH-releasing peptides (GHRP-2 and GHRP-6) do raise these hormones. That clean profile is the main reason ipamorelin is often the first-choice GHRP in research protocols.

Ipamorelin is a research compound. It is not approved for any human use. Even within research contexts, there are clear groups for whom the risk-benefit math does not work.

Some practitioners review fasting glucose and HbA1c before and during extended ipamorelin protocols. This page is not medical advice. Any decision to start, continue, or stop a research compound is between an individual and their licensed clinician.

Ipamorelin's side-effect profile is cleaner than most GH-releasing peptides. Most reports describe mild, short-lived effects. Side effects still happen, especially at higher doses or in the first weeks of use.

Some users report mild redness, stinging, or a small bump at the injection site. Rotating sites and keeping sterile technique reduces how often this happens.

Unlike GHRP-2 and GHRP-6, ipamorelin did not raise cortisol (a stress hormone), ACTH, or prolactin in lab testing at standard GH-releasing doses (Raun et al. 1998). That cleaner profile is the main reason it is generally better tolerated than the other GHRPs.

In the Beck et al. 2014 Phase II trial (117 bowel surgery patients, NCT00672074), ipamorelin given as 0.03 mg/kg IV twice daily for up to 7 days produced treatment-related adverse event rates similar to placebo. The trial did not meet its efficacy endpoint, but tolerability was not the reason the program was discontinued.

Clinical trials never tracked body-composition or recovery endpoints for ipamorelin, so there is no validated 'timeline' for those uses. The timeline below combines published pharmacokinetic data with research-community reports.

Stop or pause the protocol if persistent headaches, glucose spikes, vision changes, or carpal tunnel symptoms appear. This guide is research context, not a treatment plan.

Ipamorelin's published research is narrow. Early studies showed that it works as a selective GH secretagogue and that it has a short, well-characterized half-life. The clinical program then tested it for postoperative ileus — a digestive condition where the gut is slow to restart after surgery. The program did not show efficacy and was discontinued. No clinical trial has tested ipamorelin for the GH-optimization, body-composition, or anti-aging uses people care about today.

Ipamorelin clearly works as a GH-releasing peptide. The pharmacology is solid. But the only Phase II trial tested it for a use most people are not interested in (gut recovery after surgery), and that trial did not work. The dose ranges, schedules, and cycle lengths in this guide come from community protocols, not from validated clinical evidence.

Keep the vial upright in the back of the refrigerator, not in the door. Use bacteriostatic water (not sterile water) for multi-dose handling — the benzyl alcohol preservative helps with shelf life.

Most ipamorelin protocol problems trace back to one of five issues. Each is fixable.

If insulin spikes from a meal are still active, the GH pulse gets blunted. Protocols generally space dosing 1-2 hours from meals.

Reconstituted ipamorelin should be clear and colorless. If the solution is cloudy, has particles, or has changed color, do not use it. Reconstitute a fresh vial.

Adding more BAC water does not make the peptide weaker — it changes the concentration, so the syringe units for a given dose shift. Re-check the math against the reconstitution table. The Pep Pal calculator covers custom volumes.

Protocols generally resume at the next scheduled time after a missed dose rather than doubling up. A missed dose does not break the cycle.

Reconstituted ipamorelin needs to stay refrigerated (36-46F / 2-8C). Leaving it on the counter shortens its life. Freezing the reconstituted vial can damage the peptide unless you freeze it in single-use aliquots.

Most headaches fade within the first 1-2 weeks. Persistent headaches, including at lower doses, are a reason to pause and consult a clinician.

Ipamorelin is not FDA-approved for any human use. Its status under FDA pharmacy compounding rules has been actively debated, and the rules have shifted more than once. This section is current as of June 2026.

What this means in practice: ipamorelin is currently not eligible to be compounded by 503A pharmacies, but it is also no longer on the 'do not compound' Category 2 list. Most ipamorelin in circulation is sold by research-use suppliers, not pharmacies.

Ipamorelin and all ghrelin mimetics are prohibited substances under WADA rules, both in-competition and out-of-competition. Athletes subject to drug testing should not use ipamorelin.

Ipamorelin is not approved as a medicine in the EU, UK, Canada, or Australia. Importation rules vary. This is a research compound everywhere.

Ipamorelin is one of several compounds that raise growth hormone. Each works a bit differently. The right comparison depends on what the protocol is built around.

For a closer look at the stronger hunger signal and three-times-daily SubQ planning, see the GHRP-6 peptide guide.

Ipamorelin and CJC-1295 are not interchangeable — they work on different receptors. Ipamorelin presses the GHS-R1a (ghrelin) receptor. CJC-1295 presses the GHRH receptor. Most protocols stack them together because pressing both receptors at once creates a larger GH pulse than either one alone.

A common stack uses 100 mcg CJC-1295 (no DAC, also called Mod GRF 1-29) plus 200 mcg ipamorelin in the same shot at bedtime. Combination schedules have a different search intent from an ipamorelin-only protocol. See the dedicated CJC-1295 + Ipamorelin Dosage Chart & Stack Guide for combination-specific research context.

Tesamorelin and sermorelin are both GHRH analogs — they work on the GHRH receptor, not the GHS-R1a receptor. Tesamorelin is the only one of this group with an FDA approval (for HIV-associated lipodystrophy). Ipamorelin is not interchangeable with either. Different receptor, different protocol, different evidence base.

If you are comparing a GHRH analog plus a ghrelin-mimetic pairing, see the tesamorelin + ipamorelin blend protocol for ratio-specific reconstitution math and cycle planning.

See the compound-specific guides for Tesamorelin, Sermorelin, CJC-1295 No DAC, and CJC-1295 DAC.

Compare ipamorelin to compounds in the same family and review the most common stack:

Ipamorelin is usually discussed as a GH secretagogue pathway peptide. Monitoring focuses on IGF-1, glucose handling, lipids, thyroid context, appetite, and fluid-retention symptoms.